RecruitingNot ApplicableNCT05080166

UPLYFT For Lymphoma Survivors

An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors


Sponsor

Dana-Farber Cancer Institute

Enrollment

74 participants

Start Date

Feb 8, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • Lymphoma Survivors Phase 1 and 2:
  • Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
  • Age ≥ 18 years
  • Interval of 3 months to 24 months from completion of first-line treatment
  • In complete remission after first line of treatment
  • Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
  • Access to computer (for videoconferencing)
  • Lymphoma clinicians and mental health clinicians Phase 1:
  • Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
  • Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians

Exclusion Criteria13

  • Lymphoma Survivors Phase 1:
  • Age \< 18 years
  • Concurrent other malignancy
  • Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
  • Lymphoma Survivors Phase 2:
  • Age \< 18 years
  • Concurrent other malignancy
  • Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
  • Our study will exclude members of the following special populations:
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Interventions

OTHERInterview with Clinicians

One time, qualitative interview of clinicians for feedback on UPLYFT intervention

OTHERField Test of UPLYFT with Lymphoma Survivors

6 session of UPLYFT intervention with Lymphoma Survivors for feedback

BEHAVIORALPilot of UPLYFT with Lymphoma Survivors

6 session of UPLYFT intervention with Lymphoma Survivors


Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05080166


Related Trials